We have identified a 6-thalassemia gene that carries a novel nonsense mutation in a Chinese patient. This mutation, a G to T substitution at the first position of codon 43, changes the glutamic acid coding triplet (GAG) to a terminator codon (TAG). Based on oligonucleotide hybridization studies of 78
Introduction
The thalassemias are disorders of hemoglobin production characterized by imbalanced synthesis of a and fi chains. A large number of mutations that interfere with mRNA transcription, splicing, polyadenylation, or translation have been shown to result in a thalassemic phenotype (1) . We have studied a f3-thalassemia gene from a Chinese patient doubly heterozygous for f3-thalassemia and a nondeletion f3-thalassemia (2) by molecular cloning and expression in a heterologous transient expression system. An amber mutation at amino acid 43 was created by a G to T transversion. In addition to its deleterious effect on mRNA translation, this mutation seems to have a more profound effect on the level of mutant fl-globin mRNA in vivo than in vitro. Study of reticulocyte RNA from an individual heterozygous for this mutation demonstrated a total absence of this mutant mRNA in vivo. These findings are discussed in relation to other ,B-thalassemia genes with different nonsense mutations. 7 .5 kb Hind III fragment in Charon 28 bacteriophage (3) and subcloned it as a 3.7 kb Pst l/Bgl II fragment in the expression vector irSVplac (4) . DNA sequence analysis was performed by the dideoxy chain termination method of Sanger et al. (5) as described earlier (3) . Oligonucleotides (19 mer) , specific for the codon 43 mutation (CA-GAGGTTCTTTTAGTCCT) and the normal sequence around codon 43 (GGTTCTTTGAGTCCTTTGG), were synthesized on a DNA synthesizer (Applied Biosystems, Inc., Foster City, CA). I0-,gg samples of genomic DNA of various subjects were subjected to oligonucleotide hybridization analysis as previously described (6, 7) .
Functional studies ofthe mutant f3-globin gene. 7rSVplac recombinants containing the cloned mutant ,B-globin gene described above or a normal ,B-globin gene were cotransfected with an a-globin gene into HeLa cells at 25% confluency using the technique of DNA coprecipitation with calcium phosphate followed by glycerol shock as described earlier (8) . After 36 h, the cells were harvested and cytoplasmic RNA was extracted using methods described by Favaloro et al. (9) . The extracted RNA was used in SI nuclease mapping experiments (10, I 1) with either a 5' end-labeled double-stranded probe or a uniformly labeled single-stranded probe (see Results for description of specific probes). After Sl nuclease digestion, the protected DNA fragments were fractionated by electrophoresis in 6 or 8% polyacrylamide gels in the presence of 7 M urea. These same RNA, along with RNA isolated from reticulocytes ofan individual heterozygous for this fl-thalassemia, and another normal individual were used in RNase A protection assays. Uniformly labeled RNA probes were synthesized as described by Melton et al. (12) and hybridized to either 20 Mg oftransfected HeLa cell RNA or 5 ,g ofreticulocyte RNA at 52°C in a hybridization buffer made of 80% formamide, 0.4 M NaCl, 1 mM EDTA, and 40 mM Pipes, pH 6.7. The RNA/RNA hybrids were digested with 10 gg RNase A in 300 mM NaCl, 5 mM EDTA, and 10 mM Tris, pH 7.5 at 30°C for 30 min. The protected RNA fragments were also fractionated by electrophoresis in 6% polyacrylamide gels in the presence of 7 M urea.
Results
The DNA sequence of the cloned f3-thalassemia gene was determined from a position 100 nucleotides (nt)' upstream from the cap site to 200 nt downstream from the polyadenylation site excluding about 500 nt in the middle ofintron 2. When the DNA sequence of the cloned f,-thalassemia gene was compared with the sequence of a normal (3-globin gene (13) , five nucleotide substitutions were detected. Four of these have been previously demonstrated to represent polymorphic variations at codon 2 and IVS-2 positions 16, 74, and 666 (14) .
These polymorphisms define the fl-globin gene framework as 3
Asian. In addition, a previously unidentified G to T transversion at the first position ofcodon 43 was detected (Fig. 1) . This changes the glutamic acid coding triplet (GAG) to a stop codon (TAG) and destroys the ability of the mRNA to be translated into normal ,B-globin chains. This mutation falls within the recognition sequence ofthe restriction enzyme Hinf I and would be expected to lead to the loss of that restriction site. This was tested in a Southern blotting experiment where 10 ,ug of DNA from the cloned gene was digested with the enzyme Hinf I, run on a 2% agarose gel and probed with a 3' end-labeled DNA probe which extends from position 36 to 224 of exon 2. When DNA from a normal cloned 3-globin gene is used, a 188-nt fragment is detected (Fig. 2) ; when DNA from the cloned ,B-thalassemia gene is used, the 188-nt fragment is lost and a larger 263-nt fragment is detected instead. This fragment reflects the loss of the Hinf I site predicted by the DNA sequence data.
A synthetic oligonucleotide that can detect this mutation was synthesized and used as a probe in hybridization experiments with genomic DNA, which was obtained from a patient who carries the only remaining uncharacterized ,B-thalassemia chromosome from a panel of 78,-thalassemia chromosomes from the Chinese and Southeast Asian population (15 .. izing to the level of expression of the cotransfected a-globin gene, the mutant RNA level was determined to be 35% of the normal RNA.
In the absence of an individual homozygous for this mutation, it would be extremely difficult to determine the functional consequences of this mutation in erythroid cells in vivo.
To circumvent this problem, we used a novel approach to differentiate the fl-globin mRNA transcribed from the normal allele from the f,-globin mRNA transcribed from the mutant allele in the reticulocyte RNA ofthe simple heterozygote available for this study. This approach was suggested to us by the ability of S1 nuclease to partially recognize the single base mismatch at the site of the mutation as shown in the experiment described above. We predicted that such a mismatch may be completely recognized by a different nuclease (RNase A) if an RNA probe is used instead of a DNA probe (12) . We synthesized an antisense RNA extending from position -100 upstream from the cap site to position 49 ofexon 3 and used it in the RNase protection experiment shown in Fig. 4 . We were able to optimize the hybridization and digestion conditions to allow for 100% recognition of the mismatch between the mutant RNA and the normal sequence of the probe. Whereas the normal RNA protects the expected 223-, 143-, and 49-nt fragments (Fig. 4) , the mutant RNA shows protection of the same 143-and 49-nt fragments and the complete replacement of the 223-nt fragment by a 185-nt fragment, which results from changed. An expected 38-nt fragment, which results from cleavage of the 223-nt fragment to generate the 185-fragment, is too small to be seen on this autoradiograph. Very small amounts of the 185-nt fragment are also seen in every lane of the autoradiograph. This is probably due to overdigestion of the probe by RNase A in the AT-rich region around codon 43.
complete digestion at the site of the mismatch (Fig. 4) . Therefore, this provides us with an accurate and efficient way of distinguishing the mutant fi-globin mRNA (185-nt fragment) from the normal ,B-globin mRNA (223-nt fragment) when the same conditions of hybridization and digestion are used.
We then attempted to quantitate the level of mutant fl-globin mRNA in the reticulocyte RNA of the individual heterozygous for this mutation. When an RNase A protection experiment was performed comparing reticulocyte RNA from a normal individual with reticulocyte RNA from the affected individual under conditions that allow for 100% detection of the mismatch, no differences were noted between the two RNAs (Fig. 4) . In both the normal and patient reticulocyte lanes, a faint 185-nt band is seen that probably resulted from RNase A overdigestion at the adenosine thymidine (AT)-rich region around codon 43. However, since the normal reticulocyte RNA and the patient's RNA show an identical protection pattern, we can conclude that the level of mutant mRNA in vivo must be extremely low.
Discussion
In the course of the study of the molecular pathology of the fl-globin cluster of a family from China, we detected a f3-thalassemia globin gene on a chromosome with Chinese haplotype 2 (2, 15) . Study ofthe hemoglobin phenotype in different family members did not allow for the unambiguous characterization of this mutant gene as a f30-thalassemia or #,-thalassemia gene. Previous studies of the spectrum of the f3-thalassemia mutations in China and Southeast Asia showed that fl-thalassemia genes on chromosomes of haplotype 2 may be associated with a frameshift 41-42 mutation, nonsense 17 mutation, -28 A to G promoter mutation, or frameshift 71-72 mutation (15 (Fig. 4) . Thus, this approach provided us with a convenient assay that allows us to distinguish normal and mutant globin mRNA in vivo in erythroid cells.
When this assay was used to study reticulocyte RNA from the only surviving individual who is known to carry this mutant gene (simple heterozygote), the RNase A-protected fragments were identical in the patient's RNA and RNA from a normal control (Fig. 4) . We estimate that the sensitivity ofthis assay should allow the detection of 3% or more of mutant RNA relative to normal RNA. Therefore, we may conclude that steady state mutant mRNA levels in erythroid cells in vivo are < 3% that of normal mRNA from the normal allele. It is interesting to note that the other patient, who was shown by oligonucleotide hybridization to carry the same mutant gene, is a double heterozygote for the #'" and ,3"4 nonsense mutation.
When reticulocyte RNA from this patient was used as a substrate in a cell-free translation assay in the presence of a serine-inserting amber suppressor tRNA, a fl17Y5Ysr polypeptide product was detected that corresponded to the #17 mutant mRNA (24) . No IB3 mutant mRNA was detected in the translation products of the patient's RNA (24) . This It appears that the finding of low levels of fl-globin mRNA in vivo, transcribed from genes with nonsense mutation, is a widespread phenomenon. It also appears that there is considerable variation in the levels of mutant mRNA in reticulocytes from patients with different nonsense mutations ranging from < 1% in a patient with a single nucleotide deletion at codon 44, which produces a terminator at codon 60 (25) , to 15% in the patient with the #17 nonsense mutation (24) . There is no apparent linear relationship, however, between the level of mutant mRNA and the position of the mutation. (26) . The available experimental data suggest that missense mutations do not lead to similar decreases in levels of mutant mRNA (19) and that a relationship may exist between the ability to translate mRNA and its stability in vivo. The exact nature of the mechanism responsible for the low levels of mRNA in vivo remains to be elucidated.
